Comment from Mark Brockway

CD19 CAR-T Cell Therapy | Phase I proposal for biomarker-defined subgroup of Long COVID The opportunity Millions of Americans are disabled by Long COVID with no approved treatment and no standard of care (RECOVER Interventions Taskforce [1]). A subgroup carries a clear immunologic signature — autoantibodies and B-cell dysregulation — that points to a therapy already proven in adjacent disease. We propose extending an FDA-approved cell-therapy platform to test it. The mechanism is established, not hypothetical Long COVID is driven in part by B-cell dysregulation, de novo autoantibody production, and tissue antigen persistence that sustains chronic immune activation (Thwaites group, J Allergy Clin Immunol, 2025 [2]; Gupta et al., Comprehensive Physiology, 2025 [3]). A substantial fraction of patients carry class-switched autoantibodies within months of infection (Su et al., Cell, 2022 [4]). And when those autoantibodies are physically removed by apheresis, symptoms improve in step with falling autoantibody and inflammation levels (Achleitner et al., Molecular Psychiatry, 2023 [5]). The humoral component is real, measurable, and modifiable. The precedent is striking: In refractory autoimmune disease, a single infusion of autologous CD19 CAR-T cells produced deep B-cell depletion, normalized serology, and drug-free remission sustained beyond one year across lupus, myositis, and systemic sclerosis (Müller, Schett et al., NEJM, 2024 [6]). The effect is not transient suppression but an immunologic reset — B cells reconstitute as naïve rather than autoreactive [7]. Why CAR-T reaches where prior therapy could not: CD19 CAR-T achieves complete B-cell clearance inside lymph nodes and infiltrated tissues — the very niches where autoreactive plasmablasts hide and where antibody-based therapies fall short (Ohno et al., Ann Rheum Dis, 2025 [8]). It delivers depletion at a depth and durability that earlier approaches simply do not reach. The pathway is ready now: CD19 CAR-T products have been FDA-approved since 2017, with mature manufacturing, lymphodepletion, and clinical protocols [9]. An active autoimmune CAR-T pipeline — dozens of Phase I programs — already provides the infrastructure [7]. Adding a Long COVID arm is incremental, not greenfield. The ask: A tightly scoped Phase I safety and proof-of-mechanism study in severe, refractory, autoantibody-positive Long COVID: n≈6–12, intensive immune monitoring, biomarker-gated enrollment. First-in-indication safety and a B-cell/autoantibody reset signal — the gateway to everything that follows. Long COVID has a defined trigger, a measurable immune signature, and now a therapy that could reset exactly that signature. The case for a first trial is here. Sources 1. RECOVER Interventions Taskforce. Therapeutic trials for long COVID-19: a call to action. PMC10034329. 2. Tan/Thwaites RS, et al. Autoimmunity in long COVID. J Allergy Clin Immunol. 2025. PMID 39956285. 3. Gupta G, et al. Mechanistic Insights Into Long Covid. Comprehensive Physiology. 2025;15:e70019. 4. Su Y, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881–895. 5. Achleitner M, et al. Clinical improvement of Long-COVID following therapeutic apheresis. Molecular Psychiatry. 2023;28(7):2872–2877. 6. Müller F, Schett G, et al. CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up. NEJM. 2024. (NEJMoa2308917) 7. CAR-T cell therapy for autoimmune diseases: clinical trial landscape. Front Immunol. 2025–2026. 8. Ohno et al. CD19-CAR T-cell therapy induces deep tissue depletion of B cells. Ann Rheum Dis. 2025;84:106–14. 9. FDA first CAR-T approval, 2017; cell-therapy background, PMC13084913.